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Abstract
Objectives: We examined the hypothesis that cardiac-specific troponin-I (cTn-I), a biomarker of myocardial injury, is elevated
in patients with rheumatoid arthritis (RA).
Background: RA patients have an increased incidence of heart failure (HF). Chronic myocardial injury in RA may be a
mechanism for the development of HF.
Methods: We compared cTn-I concentrations measured by high-sensitivity immunoassay in 164 patients with RA and 90
controls, excluding prior or active heart failure. We examined the relationship between cTn-I concentrations and
cardiovascular risk factors, inflammation, and coronary artery calcium score (CACS), a measure of coronary atherosclerosis.
Results: cTn-I concentrations were 49% higher in patients with RA (median 1.15 pg/mL [IQR 0.73–1.92] than controls
(0.77 pg/mL [0.49–1.28](P,0.001). The difference remained statistically significant after adjustment for demographic
characteristics (P=0.002), further adjustment for cardiovascular (CV) risk factors (P=0.004), inflammatory markers (P=0.008),
and in a comprehensive model of CV risk factors and inflammatory markers (P=0.03). In patients with RA, cTn-I
concentrations were positively correlated with age (rho=0.359), Framingham risk score (FRS) (rho=0.366), and systolic
blood pressure (rho=0.248 (all P values #0.001)), but not with measures of inflammation or RA drug therapies. cTn-I was
significantly correlated with CACS in RA in univariate analysis, but not after adjustment for age, race, sex and FRS (P=0.79).
Further model adjustments for renal function and coronary artery disease confirmed the significance of the findings.
Conclusion: High-sensitivity cTn-I concentrations are elevated in patients with RA without heart failure, independent of
cardiovascular risk profile and inflammatory markers. Elevated troponin concentrations in RA may indicate subclinical,
indolent myocardial injury.
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Introduction
Patients with rheumatoid arthritis (RA) experience premature
mortality that is largely due to cardiovascular disease [1,2].
Cardiovascular mortality in RA is 50–60% higher compared to
the general population, and there is increased prevalence of
ischemic heart disease [3–6], There is a markedly higher
prevalence of congestive heart failure (CHF) in RA patients. For
example, in a longitudinal, population-based study, the 30-year
cumulative incidence of CHF in RA was 37.1% compared to
27.7% in controls, and CHF, rather than ischemic heart disease,
accounted for the majority of the increase in cardiovascular
mortality in RA [7].
We have previously reported increased concentrations of N-
terminal pro-brain natriuretic peptide (NT-proBNP) in patients
with RA [8]. NT-proBNP is released by myocytes in response to
myocardial stretch, and subtle increases may reflect subclinical
myocardial dysfunction [9]. Cardiac magnetic resonance imaging
has demonstrated decreased left ventricular mass in patients with
RA [10]. Thus, RA may predispose to the development of heart
failure through a pathophysiology distinct from that of ischemic
PLoS ONE | www.plosone.org 1 June 2012 | Volume 7 | Issue 6 | e38930heart disease; and chronic, indolent myocyte loss may be a central
process.
Cardiac troponins (cTn) are components of the cardiomyocyte
contractile apparatus, and circulating concentrations are elevated
in the setting of myocardial injury, such as acute coronary
syndromes (ACS) [11]. High-sensitivity (hs) cTn assays allow
measurement of troponin concentrations below conventional levels
of detection and have revealed a spectrum of circulating cTn
concentrations spanning low and high levels in both healthy
subjects and in patients with overt cardiovascular disease. Low
levels of troponin elevation, below threshold levels used to
diagnose ACS, are associated with increased CV mortality, both
in patients with diagnosed ischemic heart disease and in the
general population [12,13].
There is no information about cardiac troponin concentrations
in patients with RA. We hypothesized that concentrations high
sensitivity cardiac troponin (hs-cTn), a marker of myocyte injury,
may be elevated early in the disease process, before the
development of clinical heart failure.
Methods
Ethics Statement
The study was approved by the Institutional Review Board
(IRB) of Vanderbilt University Medical Center, and all subjects
were provided written informed consent.
Patients and Control Subjects
Subjects were participants in an ongoing study of cardiovascular
risk in RA, and detailed methods have been described previously
[14,15]. One hundred and sixty four eligible patients .18 years of
age who met the American College of Rheumatology classification
for RA and 90 control subjects without RA were studied.
Individuals with heart failure, defined as current heart failure
requiring treatment, or fulfillment of at least 2 of three following
criteria; a previous history of heart failure, use of digoxin, or use of
a diuretic, were excluded from the study.
Patients were recruited from an RA registry, by referral from
area rheumatologists, and by local advertisement. Control subjects
were recruited from among the patient’s acquaintances, by local
advertisement, and from a database of volunteers maintained by
the Vanderbilt Clinical Research Center.
Data Collection
Clinical and demographic information was acquired via
structured interview, questionnaires, physical examination, labo-
ratory tests, electron beam computed tomography (CT), and
review of medical records. Current and historic medication use
was determined from information provided by patients, and from
review of medical records. Blood pressure was recorded as the
average of 2 measurements obtained 5 minutes apart after the
subject had rested in a supine position for at least 10 minutes.
Subjects were considered hypertensive if they were taking
antihypertensive agents, or if measured systolic blood pressure
was greater than 140 mm Hg and/or diastolic pressure was
greater than 90 mm Hg. RA disease activity was assessed using the
Disease Activity Score based on evaluation of 28 joints (DAS28).
The DAS28 is a validated composite index including a 28 joint
count for tenderness and swelling, erythrocyte sedimentation rate
(ESR), and the patient’s overall assessment of wellbeing [16]. The
Framingham risk score (FRS), a composite score of traditional risk
factors that includes blood pressure, smoking status, age, and sex,
but not diabetes mellitus, was calculated.
Laboratory Tests
Blood was collected after an overnight fast for determination of
complete blood count, serum creatinine, total cholesterol, high-
density lipoprotein (HDL) cholesterol, triglycerides, homocysteine,
and low-density (LDL) cholesterol at the Vanderbilt University
Medical Center clinical laboratory. In patients with RA, CRP and
Westergren ESR were measured by the hospital laboratory, and
medical records reviewed to determine the presence or absence of
rheumatoid factor (RF). Before 2003, the laboratory did not use a
high-sensitivity CRP assay, and low concentrations were reported
as ,3 mg/L. Thus, in 40 patients with CRP reported as ,3 mg/
L, concentrations were re-measured by ELISA (Millipore), and the
resulting data were used in the current study analysis. High
sensitivity cardiac specific troponin-I (hs-cTn-I) was assayed using
the Erenna
R System (Singulex Corp, Alameda, CA) by technicians
blinded to the clinical data. The limit of detection and the 10%
coefficient of variation were 0.1 pg/mL and 0.7 pg/mL, respec-
tively. TNFa, interleukin-6 (IL-6), and NT-pro-BNP concentra-
tions were measured by multiplex enzyme-linked immunosorbent
assay (Linco Research/Millipore, St. Louis, MO).
Coronary Artery Calcification
All subjects underwent tomographic imaging with a c-150
scanner (GE/Imatron, South San Francisco, CA) as described
previously [14]. Scans were evaluated by a single investigator
blinded to patient clinical status. The degree of calcified plaque
was calculated as described previously; the sum of partial scores of
all coronary artery lesions provided an overall coronary artery
calcium score (CACS) for each patient [13].
Statistical Analysis
Descriptive statistics were calculated as the median with the
interquartile range (median [IQR]) or mean 6SD) according to
the distribution of the continuous variables. Wilcoxon rank-sum
tests were used to compare continuous variables. Person Chi-
square tests were used to compare categorical variables. We
assessed the correlation between hs-cTn-I concentration and
cardiovascular risk factors (body mass index (BMI), high density
lipoprotein (HDL) and low density lipoprotein (LDL) cholesterol,
triglycerides (TG), diabetic status, homocysteine, lipoprotein(a),
inflammation markers (CRP, IL-6 and TNFa) with Spearman’s
rank correlation test separately for patients with RA and control
subjects. To assess the independent association between RA status
and hs-cTn-I concentration, we used 4 multivariable linear
regression models with a priori defined covariates. Those models
adjusted for:
Model 1. Age, race, and sex (base model);
Model 2. Base model and cardiovascular risk factors (body
mass index (BMI), high density lipoprotein (HDL) and low density
lipoprotein (LDL) cholesterol, triglycerides (TG), diabetic status,
homocysteine, lipoprotein(a), current smoking status, and
hypertension (HTN));
Model 3. Base model and markers of inflammation (C
reactive protein (CRP), interleukin-6 (IL-6), and tumor necrosis
factor-alpha (TNFa); and
Model 4. Base model, cardiovascular risk factors (as in Model
2), markers of inflammation (as in Model 3), and NT-proBNP.
Among the RA group, the association between hs-cTn-I
concentrations and CACS was examined using the proportional
odds model with CACS as the dependent variable, and were
adjusted for age, race, sex, and FRS. Concentrations of hs-cTn-I,
triglycerides, homocysteine, CRP, TNF-a, and IL-6 were natural
logarithm-transformed to improved normality. All calculations
were performed using R version 2.10.0 (http://www.r-project.org)
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significant.
Sensitivity Analysis for Possible Confounders
Because cardiac troponin is renally cleared, the results of the
study could be confounded in patients with poor renal function.
To account for renal function, the statistical models were analyzed
by including the estimated glomerular filtration rate (Modification
of Diet in Renal Disease calculation) in the model. Further, to
control for the presence of known cardiovascular disease in the
study subjects, the statistical models were re-analyzed, excluding
patients with a diagnosed cardiovascular disease (22 RA patients,
8 control patients excluded).
Results
Patient Characteristics
Patients with RA (n=164) and control subjects (n=90) were of
similar age and had a similar sex distribution (Table 1). As
reported previously in this cohort, NT-BNP, CRP, TNFa, IL-6,
homocysteine, and CACS were significantly higher in RA than in
control subjects [9,14,15]. A history of ischemic cardiovascular
disease (stroke, myocardial infarction, angina) or a coronary
procedure (coronary artery bypass graft or angioplasty) was
present in 13% of patients with RA and 9% of controls (P=0.29).
High Sensitivity cTn-I Concentrations and Clinical
Variables in RA Patients and Controls
High sensitivity cTn-I concentrations were significantly higher
in patients with RA (median 1.15 pg/mL [IQR 0.73–1.92] than
controls (0.77 pg/mL [0.49–1.28](P,0.001) (Figure 1). Hs cTn-I
remained significantly higher in RA patients after adjustment for
age, race, and sex (p=0.002)(Figure 2- Model 1); age, race,
sex and cardiovascular risk factors (p=0.004)(Figure 2-
Model 2); age, race, sex, and markers of inflammation
(p=0.008)(Figure 2- Model 3); and age, race, sex, CV risk
factors, markers of inflammation, and NT-proBNP
(p=0.029)(Figure 2- Model 4). Rheumatoid factor was measured
Table 1. Clinical Characteristics of Study Subjects.
Characteristic RA (n=164) Control (n=90) P-Value
Demographics (mean±SD)
Age (years) 54.0611.8 52.9611.3 0.422
Female Sex, no. (%) 112 (68%) 56 (62%) 0.328
Caucasian, no. (%) 147 (90%) 76 (84%) 0.227
Non-smoker, no. (%) 39 (24%) 8 (9%) 0.003
Disease Activity Score (DAS28) 3.9 (2.6–4.9) - -
Disease Duration (years) 3 (2–18) - -
Cardiovascular Risk Factor
Hypertension, no. (%) 85 (52%) 35 (39%) 0.048
Systolic BP, mmHg (mean6SD) 132.8620.2 129.1617.5 0.133
Diastolic BP, mmHg (mean6SD) 74.81610.89 72.7468.82 0.185
CVD or coronary procedure, no. (%) 22 (13%) 8 (9%) 0.285
Diabetic, no. (%) 18 (11%) 4 (4%) 0.077
On NSAIDS, no. (%) 54 (33%) 36 (40%) 0.26
BMI, kg/m
2 (mean6SD) 29.1466.63 28.5465.88 0.543
CACS (Agatston Units) (median, IQR) 2.7 (0.0–150.4) 0.0 (0.0–19.2) 0.021
RA treatment regimens
Current corticosteroid use, no. (%) 88 (54%) - -
Current methotrexate use, no. (%) 118 (72%) - -
Current antimalarial use, no. (%) 42(26%) - -
Current anti-TNF agent use, no. (%) 34 (21%) - -
Laboratory Measurements (median, IQR)
HDL (mg/dL) 43.0 (37.0–54.0) 45.0 (38.0–54.0) 0.705
LDL (mg/dL) 111.0 (88.5–135.5) 121.0 (104.0–140.0) 0.031
Homocysteine (mmol/L) 2.317 (2.083–2.477) 2.104 (1.978–2.270) ,0.001
Creatinine (mg/dL) 0.800 (0.700–0.900) 0.800 (0.700–0.900) 0.408
TNFa (pg/mL) 5.41 (2.72–11.00) 3.38 (2.35–4.67) ,0.001
IL-6 (pg/mL) 13.81 (4.41–42.36) 4.25 (1.15–18.27) ,0.001
CRP (mg/L) 4.00 (1.19–11.00) 0.55 (0.21–1.53) ,0.001
NT-BNP (pg/mL) 89.7 (28.7–232.3) 18.0 (3.2–39.0) ,0.001
hs-cTn-I (pg/mL) 1.150 (0.730–1.922) 0.770 (0.492–1.277) ,0.001
P values were determined by Wilcoxon’s rank sum test or chi-square test.
doi:10.1371/journal.pone.0038930.t001
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different among RA patients in whom rheumatoid factor was
present (1.17 [0.73–1.99] pg/ml, n=112 (71%)), or absent (1.09
[0.73–1.41] pg/ml, n=45 (29%))(p=0.28).
Sensitivity Analysis
Sensitivity analyses were performed adjusting for renal function
(MDRD) and excluding study subjects with previous CV disease.
The finding that hs-cTn-I was higher in RA patients compared to
controls remained statistically significant in models 1–4 (all P
values ,0.05).
Association between hs-cTn-I Concentrations and Clinical
Variables
In RA, hs-cTn-I concentrations were positively correlated with
age, systolic BP, CACS and NT-proBNP; and in control subjects
with systolic BP, serum creatinine, and CACS, but not with age or
NT-proBNP (Table 2). There was no significant difference in hs-
cTn-I concentrations among RA patients who were or were not
currently receiving methotrexate, anti-TNF drugs, hydroxychlor-
oquine, and corticosteroids (Table 3).
High Sensitivity cTn-I and Coronary Artery Calcification
Score (CACS)
Although CACS was significantly correlated with hs-cTn-I
concentrations in both patients with RA (rho=0.33, P,0.001)
and control subjects (rho=0.24, P=0.005), there were no
statistically significant associations after multivariable model
adjustment for age, race, sex and FRS in both RA (P=0.79)
and control subjects (P=0.43).
Discussion
The major finding of this study was that concentrations of high
sensitivity cardiac troponin-I, a biomarker of cardiac injury, were
higher in patients with RA compared to controls. This difference
in troponin-I concentrations between patients with RA and
controls remained statistically significant after adjustment for
demographic variables, inflammation, renal function, coronary
artery disease, and cardiovascular risk factors.
Figure 1. Unadjusted Troponin Concentrations. Boxplot of troponin concentrations (pg/mL) for RA subjects and controls, demonstrating
elevated troponin concentrations in RA patients compared to controls (p=0.0006). Presented as 25th quartile, median, 75th quartile. Fences drawn to
nearest value not exceeding 1.5 interquartile range. Observations beyond fences are plotted.
doi:10.1371/journal.pone.0038930.g001
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suspected of having acute coronary syndrome (ACS), elevated cTn
concentrations have almost complete specificity for myocardial
tissue. Consensus guidelines recommend that cardiac troponin
concentrations corresponding to the 99
th percentile of a healthy
population (commonly 0.03 mg/L or 30 pg/mL) be used as the
threshold for defining an abnormal elevation [17–20]. More
recently, high-sensitivity troponin assays allow measurement of
troponin with detection limits 10-fold lower than conventional
assays, and are thus capable of identifying subclinical myocardial
injury and CV risk [12]. Low level hs-cTn elevation, is associated
with increased risk of heart failure and cardiovascular death in
patients with stable coronary artery disease [13]. Similarly, in
several community-based studies, the troponin concentration
detected was predictive of long-term cardiovascular outcomes
[21,22]. For example, in the Atherosclerosis Risk in Communities
(ARIC) cohort, cTn concentrations of 6–8 pg/mL were associated
with significantly increased risk for coronary heart disease, heart
failure, and mortality [22].
Patients with RA have shorter life expectancy, more ischemic
heart disease and heart failure, and higher cardiovascular
mortality compared to the general population [23,24,25]. The
increased risk of heart failure in patients with RA is not explained
by traditional cardiovascular risk factors, or solely by the presence
of ischemic heart disease [8,26,27]. Interestingly, a recent cardiac
MRI study reported lower myocardial mass in patients with RA
compared to age matched controls [10], suggesting chronic
Table 2. Correlation between hs-cTn-I and clinical variables in
patients with RA and controls.
RA Patients
(n=164) Controls (n=90)
Variable rho P* rho P*
Age 0.359 ,0.001 0.172 0.104
Body mass index 20.142 0.069 0.026 0.806
Systolic blood pressure 0.248 0.001 0.297 0.005
Coronary calcium score 0.330 ,0.001 0.298 0.005
HDL cholesterol 0.066 0.402 20.056 0.605
LDL cholesterol 0.174 0.027 0.154 0.15
Homocysteine 0.166 0.035 0.088 0.409
Creatinine 0.145 0.064 0.306 0.003
TNFa 0.148 0.061 20.106 0.321
IL-6 0.093 0.243 20.144 0.188
C-reactive protein 20.086 0.275 0.166 0.119
NT-proBNP 0.255 0.001 0.062 0.567
Disease Duration 0.197 0.012 N/A N/A
DAS28 0.037 0.638 N/A N/A
Erythrocyte sedimentation rate 20.014 0.863 N/A N/A
*P values by Spearman’s correlation coefficient test.
doi:10.1371/journal.pone.0038930.t002
Table 3. Concentrations of hs-cTn-I in patients with RA
receiving different drugs (n=164).
Current Drug Therapy n hs-cTn-I, pg/mL P value*
On methotrexate 118 1.170 (0.732–1.802) 0.897
Not on methotrexate 46 1.08 (0.723–1.997)
On anti-TNF drug 34 0.980 (0.750–1.627) 0.734
Not on anti-TNF drug 130 1.175 (0.723–1.952
On hydroxychloroquine 42 1.095 (0.730–1.655) 0.428
Not on hydroxychloroquine 122 1.170 (0.732–1.927
On corticosteroids 88 1.175 (0.737–1.942) 0.343
Not on corticosteroids 76 1.115 (0.728–1.787)
*Wilcoxon’s rank sum test.
doi:10.1371/journal.pone.0038930.t003
Figure 2. Multivariable Linear Regression Troponin Models for RA Patients vs Controls. Model 1: Adjusted for patient age, race, gender
(p=0.002); Model 2: Adjusted for age, race, gender, and cardiovascular risk factors (p=0.004); Model 3: Adjusted for age, race, gender and markers of
inflammation (p=0.008); Model 4: Adjusted for age, race, gender, cardiovascular risk factors, markers of inflammation, and NT-proBNP (p=0.03).
doi:10.1371/journal.pone.0038930.g002
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RA. Our finding of increased circulating hs-cTn would be
concordant with that hypothesis.
The mechanistic explanation for elevated troponin concentra-
tions in RA is not known. There are several proposed myocardial
mechanisms for cTn release, including subendocardial ischemia
leading to myocyte necrosis, cardiomyocyte injury from inflam-
matory cytokines, hibernating myocardium, and apoptosis [28–
32]. We found no significant association between hs-cTn-I levels
and inflammatory cytokines, acute phase reactants, or a disease
activity score (Table 2). This suggests that active inflammation
may not be the primary driver of troponin elevation in RA.
Viable cardiomyocytes, without necrosis, can release cTn as an
intact protein by a stretch-related mechanism mediated by
integrins [33]. Thus, underlying hemodynamic stress leading to
increased myocardial stretch may play a role in the elevated
troponin concentrations in RA. The mechanism for BNP release
from myocytes is also hypothesized to be stretch related. Indeed,
we previously reported that NT-proBNP concentrations are
elevated in patients with RA [9], and in the present study, hs-
cTn-I and NT-proBNP concentrations were significantly corre-
lated. However, the concentrations of hs-cTn-I remained signif-
icantly higher in patients with RA than controls, even when NT-
proBNP was included in the statistical model. This suggests that
there may be additional mechanisms underlying elevated hs-cTn-I
in RA, compared to those that drive NT-proBNP.
Patients with RA have an increased risk of ischemic heart
disease. Thus, pre-existing heart disease could account for
differences between RA patients and controls. Indeed, we found
a significant correlation between hs-cTn-I concentrations and
CACS, a measure of coronary artery atherosclerosis. However, the
association between hs-cTn-I concentrations and CACS was not
significant after adjustment for age, sex, race, and Framingham
risk score. Furthermore, when we adjusted for cardiovascular risk
factors, hs-cTn-I concentrations remained significantly higher in
patients with RA than controls.
These observations suggest that the clinical and subclinical
measures of heart disease we studied do not fully account for the
increased concentrations of hs-cTn-I concentrations in RA
patients. The most plausible explanation is that elevated hs-cTn-
I concentrations in RA patients reflect subclinical myocardial
damage, perhaps reflected by small vessel disease or fibrosis, in
addition to that accrued from hypertension, age, and other
cardiovascular risk factors.
Another consideration is whether the increased concentrations
of hs-cTn-I in RA could be artifactual since rheumatoid factor and
other heterophilic antibodies can potentially interfere with
antibody-based immunoassays by nonspecific binding with detec-
tion agents. Rheumatoid factor, present in 71% of patients in this
study, however, was not associated with higher circulating hs-cTn-
I. Furthermore, in developing the assay, we designed the assay
buffers to contain blockers to suppress interference from hetero-
phile antibodies, including RF and human anti-mouse antibodies.
The assay was tested experimentally with samples known to
contain high concentrations of such interfering substances and no
interference was observed.
A limitation of the study was that we did not have measures of
myocardial structure or function. Furthermore, the study was
cross-sectional, and thus provided no information about long-term
outcomes. We could not evaluate the temporal relationship
between inflammatory markers and troponin. We cannot, for
example, exclude the possibility that waxing and waning
concentrations of inflammatory mediators during exacerbations
of RA may affect hs-cTn-I concentrations. The patients in this
study had relatively well-controlled disease and it is possible that
high levels of inflammation, as occurs in poorly controlled disease,
may affect hs-cTn-I concentrations.
In conclusion, high-sensitivity cTn-I concentrations are elevated
in patients with RA without heart failure, independent of
cardiovascular risk profile and inflammatory markers. Elevated
troponin concentrations in RA may indicate subclinical, indolent
myocardial injury.
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